A recent study demonstrated the predictive potential of these metabolites, showing that a specific ratio of metabolites can classify IBD and non-IBD samples.13 Furthermore, recent studies have shown that changes in bile acid levels are predictive of therapeutic response,14 e.g., CD patients responding to TNF-alpha inhibitors exhibited higher serum levels of secondary bile acids.15 The gene discussed is TNF; the disease is inflammatory bowel disease.